A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Luc...
10x Genomics (NASDAQ:TXG) reported a first-quarter revenue increase excluding prior-year settlement revenue and used its earnings call to emphasize the launch of Atera, a new spatial biology instrument platform that management described as the most significant product introduction in the company’s h
What Happened? Shares of biotech company 10x Genomics (NASDAQ:TXG) fell 5.3% in the afternoon session after its first-quarter results, although beating expec...
Biotech company 10x Genomics (NASDAQ:TXG) announced better-than-expected revenue in Q1 CY2026, but sales fell by 2.6% year on year to $150.8 million. The com...
Biotech company 10x Genomics (NASDAQ:TXG) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, but sales fell by 2.6% year on year to $150.8 mi...
Biotech company 10x Genomics (NASDAQ:TXG) will be announcing earnings results this Thursday after the bell. Here’s what to look for. 10x Genomics beat analys...
Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to conv...
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face c...
What Happened? Shares of biotech company 10x Genomics (NASDAQ:TXG) fell 5.4% in the afternoon session after a key industry peer, Thermo Fisher Scientific (TM...
Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements...
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that ...
What Happened? A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones Industrial Average fell sharply as in...
10x Genomics has had an impressive run over the past six months. While the S&P 500 has been flat, the stock has returned 39.8% and now trades at $18.24. This...
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient...
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from eleva...
The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However,...
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the life sciences tools & services stocks, including 10x Genomics (NASDAQ:TXG) and its ...
WALTHAM, MA — In a market defined by shifting geopolitical alliances and a renewed "flight to quality," Thermo Fisher Scientific (NYSE:TMO) has once again asserted its dominance as the bedrock of the life sciences sector. Reporting its fourth-quarter 2025 results on January 29, 2026, the company delivered a robust earnings
